Charles Schwab Trust Co Has $248,000 Position in Eli Lilly and Company (NYSE:LLY)

Charles Schwab Trust Co raised its position in Eli Lilly and Company (NYSE:LLY) by 42.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 321 shares of the company’s stock after buying an additional 95 shares during the quarter. Charles Schwab Trust Co’s holdings in Eli Lilly and Company were worth $248,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in LLY. Ballentine Partners LLC boosted its position in shares of Eli Lilly and Company by 1.6% in the fourth quarter. Ballentine Partners LLC now owns 17,260 shares of the company’s stock valued at $13,325,000 after acquiring an additional 279 shares during the period. Atwood & Palmer Inc. boosted its holdings in Eli Lilly and Company by 3.9% in the 4th quarter. Atwood & Palmer Inc. now owns 532 shares of the company’s stock valued at $411,000 after purchasing an additional 20 shares during the period. ZWJ Investment Counsel Inc. grew its position in shares of Eli Lilly and Company by 0.6% during the 4th quarter. ZWJ Investment Counsel Inc. now owns 6,415 shares of the company’s stock worth $4,952,000 after purchasing an additional 36 shares in the last quarter. Pure Financial Advisors LLC grew its position in shares of Eli Lilly and Company by 45.0% during the 4th quarter. Pure Financial Advisors LLC now owns 3,407 shares of the company’s stock worth $2,630,000 after purchasing an additional 1,058 shares in the last quarter. Finally, Tudor Financial Inc. increased its holdings in shares of Eli Lilly and Company by 140.3% during the fourth quarter. Tudor Financial Inc. now owns 1,086 shares of the company’s stock worth $839,000 after purchasing an additional 634 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $753.65 on Thursday. The stock’s 50-day moving average is $777.46 and its 200-day moving average is $851.61. The stock has a market cap of $715.46 billion, a P/E ratio of 81.48, a price-to-earnings-growth ratio of 1.52 and a beta of 0.41. Eli Lilly and Company has a 1-year low of $614.82 and a 1-year high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company’s revenue was up 20.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.10 earnings per share. Equities research analysts anticipate that Eli Lilly and Company will post 12.98 earnings per share for the current year.

Eli Lilly and Company declared that its Board of Directors has initiated a share buyback program on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.80%. Eli Lilly and Company’s payout ratio is presently 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on LLY. Barclays reduced their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Truist Financial increased their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. Wolfe Research assumed coverage on shares of Eli Lilly and Company in a research report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price objective for the company. Citigroup increased their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Finally, Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,002.22.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.